Revenio Group Oyj - Other information disclosed according to the rules of the Exchange

Revenio Group Corporation: CE marking for asthma product Ventica

Revenio Group Corporation, Stock Exchange Release, January 10, 2017 at 09:00 am


CE MARKING FOR ASTHMA PRODUCT VENTICA®

A CE marking has been granted for Revenio's asthma product Ventica®. This will
enable the sales and marketing of the product, as well as clinical studies of
broader scope in Finland and elsewhere in Europe.

Ventica® is designed to assist in the diagnosis of asthma in small children in
particular, as well as the evaluation of medication administered during
treatment. Measurement of pulmonary function is an important part of treating
asthma, but spirometry is unsuitable for children. Asthma symptoms tend to vary
on an hourly basis. Ventica measures the patient's expiratory profile during the
night, providing doctors with important information on the effectiveness of
asthma medication.

"Our development of the asthma product, Ventica, has proceeded according to plan
and we have prepared a product for launch on the European markets. We can begin
taking the related measures now that we have been awarded a CE marking. We are
now in the important stage of obtaining more clinical evidence in support of
sales. The rapid product development process and the granting of a CE marking
show that our operating model and documentation are in good shape," explains
Timo Hildén, President & CEO of Revenio Group.

Revenio Group Corporation

For further information, please contact:
Timo Hildén, President & CEO
Tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi
www.ventica.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi


The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.

[]